Skip to main content

Table 2 Sensitivity, specificity, positive and negative predictive value of all studied markers in three “clinical situations”.

Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
Crohn's disease (n  =  913) vs. ulcerative colitis (n  =  272)
 gASCA (⩾50 EU) 56.4 90.4 95.2 38.2
 ALCA (⩾70 EU) 17.7 93.0 89.5 25.2
 ACCA (⩾90 EU) 20.7 84.9 82.2 24.2
 AMCA (⩾90 EU) 28.1 82.4 84.3 25.5
 Omp (⩾25 EU) 29.1 80.5 83.4 25.3
 pANCA* 37.3 90.0 52.6 82.8
IBD (n  =  1225) vs healthy controls (n  =  200)
 gASCA (⩾50 EU) 44.8 99.0 99.6 22.7
 ALCA (⩾70 EU) 14.9 98.5 98.4 15.9
 ACCA (⩾90 EU) 19.3 85.5 89.1 14.7
 AMCA (⩾90 EU) 25.9 92.0 95.2 16.8
 Omp (⩾25 EU) 27.0 93.5 96.2 17.3
 pANCA 17.2 97.5 97.7 16.2
IBD (n  =  1225) vs non‐IBD GI (n  =  113)
 gASCA (⩾50 EU) 44.8 98.2 99.6 14.1
 ALCA (⩾70 EU) 14.9 99.1 99.5 9.7
 ACCA (⩾90 EU) 19.3 84.1 92.9 8.8
 AMCA (⩾90 EU) 25.9 92.9 97.5 10.4
 Omp (⩾25 EU) 27.0 75.2 92.2 8.7
 pANCA 17.2 93.8 96.8 9.4

ACCA, Anti‐chitobioside carbohydrate antibody; ALCA, anti‐laminaribioside carbohydrate antibody; AMCA, anti‐mannobioside carbohydrate antibody; EU, ELISA units; gASCA, anti‐Saccharomyces cerevisiae antibody; GI, gastrointestinal inflammation; IBD, inflammatory bowel disease; Omp, outer membrane porin; pANCA, perinuclear anti‐neutrophilic cytoplasmic antibody.

*pANCA accuracy to detect ulcerative colitis.